Q4 Earnings Forecast for Arvinas Issued By Leerink Partnrs

Arvinas, Inc. (NASDAQ:ARVN) – Investment analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for shares of Arvinas in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will earn ($0.93) per share for the quarter. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. Leerink Partnrs also issued estimates for Arvinas’ FY2027 earnings at $1.05 EPS.

ARVN has been the subject of a number of other research reports. Guggenheim reaffirmed a “buy” rating on shares of Arvinas in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research note on Wednesday, December 11th. Barclays cut their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Stephens assumed coverage on Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 target price for the company. Finally, Oppenheimer cut their price target on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $61.45.

Arvinas Price Performance

ARVN opened at $18.70 on Friday. The firm has a 50 day simple moving average of $19.75 and a 200 day simple moving average of $23.67. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $53.08. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -4.00 and a beta of 1.88.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. M&T Bank Corp lifted its position in Arvinas by 16.7% in the 4th quarter. M&T Bank Corp now owns 31,673 shares of the company’s stock valued at $608,000 after acquiring an additional 4,536 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Arvinas by 1.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 536,112 shares of the company’s stock valued at $10,277,000 after purchasing an additional 5,443 shares during the period. Handelsbanken Fonder AB lifted its holdings in shares of Arvinas by 16.9% in the fourth quarter. Handelsbanken Fonder AB now owns 22,825 shares of the company’s stock valued at $438,000 after purchasing an additional 3,300 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Arvinas by 0.9% during the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock worth $1,685,000 after buying an additional 754 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Arvinas by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock worth $279,000 after buying an additional 1,367 shares in the last quarter. Institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.